LTIP awards

Hikma Pharmaceuticals Plc 03 April 2007 Hikma Pharmaceuticals PLC - LTIP Awards LONDON, 3 April 2007: Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) announces that the Remuneration Committee has made the following awards under the Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan (the 'LTIP') to Persons Discharging Managerial Responsibility ('PDMRs') of the Company. Awards were made on 2 April 2007 at a price of £3.87 per ordinary share as follows:- Name of PDMR Number of LTIP Shares Bassam Kanaan 30,000 Nabil Rizk 30,000 Taghreed Al-Shunnar 25,000 Majda Labadi 25,000 Gabriel Kalisse 25,000 Mike Raya 25,000 The shares subject to the LTIP awards will only be released to the participants in three years time, subject to their continued employment and the satisfaction of the comparative Total Shareholder Return ('TSR') performance target. Participants will only receive the full benefit of their share incentives if TSR performance against the Comparator Group is at least at the upper quartile. - ENDS - Enquiries: Hikma Pharmaceuticals PLC Henry Knowles +44 20 7399 2760 Company Secretary Susan Ringdal +44 20 7399 2760 Investor Relations Director About Hikma Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products. Hikma's operations are conducted through three businesses: Generic, Branded and Injectable Pharmaceuticals. Hikma's operations are based principally in the United States, the Middle East and North Africa ('MENA') region and Europe. In 2006, the Group had revenue of $317 million and profit attributable to shareholders of $54.5 million. For news and other information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock Exchange
UK 100

Latest directors dealings